These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 10800398)
1. h-Caldesmon as a specific marker for smooth muscle tumors. Comparison with other smooth muscle markers in bone tumors. Watanabe K; Tajino T; Sekiguchi M; Suzuki T Am J Clin Pathol; 2000 May; 113(5):663-8. PubMed ID: 10800398 [TBL] [Abstract][Full Text] [Related]
2. Is anti-h-caldesmon useful for distinguishing smooth muscle and myofibroblastic tumors? An immunohistochemical study. Ceballos KM; Nielsen GP; Selig MK; O'Connell JX Am J Clin Pathol; 2000 Nov; 114(5):746-53. PubMed ID: 11068549 [TBL] [Abstract][Full Text] [Related]
3. [Immunohistochemical differentiation of leiomyocellular tumors and tumors with myogenic differentiation]. Povýsil C; Ciprová V; Dundr P; Horáková M Cesk Patol; 2003 Apr; 39(2):64-8. PubMed ID: 12874903 [TBL] [Abstract][Full Text] [Related]
4. h-Caldesmon as a specific marker of smooth muscle cell differentiation in some soft tissue tumors of the skin. D'Addario SF; Morgan M; Talley L; Smoller BR J Cutan Pathol; 2002 Aug; 29(7):426-9. PubMed ID: 12139638 [TBL] [Abstract][Full Text] [Related]
5. h-Caldesmon in leiomyosarcoma and tumors with smooth muscle cell-like differentiation: its specific expression in the smooth muscle cell tumor. Watanabe K; Kusakabe T; Hoshi N; Saito A; Suzuki T Hum Pathol; 1999 Apr; 30(4):392-6. PubMed ID: 10208459 [TBL] [Abstract][Full Text] [Related]
6. Specific but variable expression of h-caldesmon in leiomyosarcomas: an immunohistochemical reassessment of a novel myogenic marker. Hisaoka M; Wei-Qi S; Jian W; Morio T; Hashimoto H Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):302-8. PubMed ID: 11759055 [TBL] [Abstract][Full Text] [Related]
7. Calponin and h-caldesmon expression in atypical fibroxanthoma and superficial leiomyosarcoma. Sakamoto A; Oda Y; Yamamoto H; Oshiro Y; Miyajima K; Itakura E; Tamiya S; Honda Y; Ishihara A; Iwamoto Y; Tsuneyoshi M Virchows Arch; 2002 Apr; 440(4):404-9. PubMed ID: 11956822 [TBL] [Abstract][Full Text] [Related]
8. Expression of smooth muscle markers in so called malignant fibrous histiocytomas. Hasegawa T; Hasegawa F; Hirose T; Sano T; Matsuno Y J Clin Pathol; 2003 Sep; 56(9):666-71. PubMed ID: 12944549 [TBL] [Abstract][Full Text] [Related]
9. [Significance of SATB2 in the pathologic diagnosis of osteosarcoma]. Li M; Cai YP; Lu KY; Chen Y; Zhu X; Yin Y; Tang J Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):631-5. PubMed ID: 27646893 [TBL] [Abstract][Full Text] [Related]
10. Pseudosarcomatous myofibroblastic tumor and myosarcoma of the urogenital tract. Watanabe K; Baba K; Saito A; Hoshi N; Suzuki T Arch Pathol Lab Med; 2001 Aug; 125(8):1070-3. PubMed ID: 11473460 [TBL] [Abstract][Full Text] [Related]
11. Differential expression of smooth muscle myosin, smooth muscle actin, h-caldesmon, and calponin in the diagnosis of myofibroblastic and smooth muscle lesions of skin and soft tissue. Perez-Montiel MD; Plaza JA; Dominguez-Malagon H; Suster S Am J Dermatopathol; 2006 Apr; 28(2):105-11. PubMed ID: 16625070 [TBL] [Abstract][Full Text] [Related]
12. Differential expression of high molecular weight caldesmon in colorectal pericryptal fibroblasts and tumour stroma. Nakayama H; Miyazaki E; Enzan H J Clin Pathol; 1999 Oct; 52(10):785-6. PubMed ID: 10674042 [TBL] [Abstract][Full Text] [Related]
13. Calponin and h-caldesmon in soft tissue tumors: consistent h-caldesmon immunoreactivity in gastrointestinal stromal tumors indicates traits of smooth muscle differentiation. Miettinen MM; Sarlomo-Rikala M; Kovatich AJ; Lasota J Mod Pathol; 1999 Aug; 12(8):756-62. PubMed ID: 10463476 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical study of bone GLA protein in primary bone tumors. Iwasaki R; Yamamuro T; Kotoura Y; Okumura H; Kasai R; Nakashima Y Cancer; 1992 Aug; 70(3):619-24. PubMed ID: 1320449 [TBL] [Abstract][Full Text] [Related]
15. Usefulness of β-catenin expression in the differential diagnosis of osteosarcoma, osteoblastoma, and chondroblastoma. Erdogan KE; Pacheco M; Gambarotti M; Magagnoli G; Sbaraglia M; Frisoni T; Righi A; Dei Tos AP Virchows Arch; 2021 Sep; 479(3):529-535. PubMed ID: 33511430 [TBL] [Abstract][Full Text] [Related]
16. Frequent expression of smooth muscle markers in malignant fibrous histiocytoma of bone. Ueda T; Araki N; Mano M; Myoui A; Joyama S; Ishiguro S; Yamamura H; Takahashi K; Kudawara I; Yoshikawa H J Clin Pathol; 2002 Nov; 55(11):853-8. PubMed ID: 12401825 [TBL] [Abstract][Full Text] [Related]
17. [Pleomorphic and dedifferentiated leiomyosarcoma: a clinicopathologic analysis]. Sun M; Liu JG; Weng QY; Yu L; Wang J Zhonghua Bing Li Xue Za Zhi; 2018 Feb; 47(2):87-93. PubMed ID: 29429158 [No Abstract] [Full Text] [Related]
18. Potential utility of CD5 immunohistochemical staining in the diagnosis of muscle tumors. McNab PM; DeMers NM; Schlauder S; Morgan M; Nasir A; Coppola D; Bui MM Ann Clin Lab Sci; 2009; 39(2):108-13. PubMed ID: 19429795 [TBL] [Abstract][Full Text] [Related]